Notion of 'Global' Microbial Resistance May Be Oversimplified

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 11
Volume 4
Issue 11

MONTREAL-The rising worldwide incidence of microbial resistance stems from a wide variety of causes and does not reflect a single global trend or etiology, Prof. Dr. Bernd Wiedemann, University of Bonn, Germany, said at a plenary session of the 19th International Congress of Chemotherapy.

MONTREAL-The rising worldwide incidence of microbial resistancestems from a wide variety of causes and does not reflect a singleglobal trend or etiology, Prof. Dr. Bernd Wiedemann, Universityof Bonn, Germany, said at a plenary session of the 19th InternationalCongress of Chemotherapy.

Although it may be tempting to oversimplify the situation andpin the blame on an overall cause, such as the misuse, overuse,or inappropriate use of antibiotics, Dr. Wiedemann claims thatlocal patterns of resistance arise from specific etiologies andmust therefore be attacked singly.

One possible cause of increased resistance, for example, may betraced to medical advances, such as organ transplantation andcancer chemotherapy, that have paradoxically resulted in patientswho are sicker and more vulnerable to infection with resistantorganisms.

Although resistance to antibiotics has been reported in many areasof the world, Dr. Wiedemann said that these reports are basedon highly variable standards. Comparisons are virtually meaninglessin the face of different testing methods, breakpoints, surveillancetechniques, and government regulations.

Establishing microbiologic standards is important, Dr. Wiedemannsaid, since "good epidemiology" is necessary to reallyunderstand global patterns and begin to devise preventive strategies.

He noted that specific migrations of resistant bacterial clonesaround the world have been documented. A resistant Streptococcuspneumoniae was traced, for instance, from South Africa toEurope and the United States, while a gentamicin-resistant Pseudomonasaeruginosa traversed the globe eastward, also arising in SouthAfrica, but spreading to Israel, Thailand, and Singapore.

Dr. Wiedemann said that some trends bear watching because of theirpotential impact on worldwide public health. The rising incidenceof resistant tuberculosis in drug addicts, he said, may eventuallyrepresent a serious problem in many countries, as might methicillin-resistantstaphylococci, vancomycin-resistant enterococci, penicillin- andtetracycline-resistant gonococci, and multiresistant Enterobacteriaceaeand Pseudomonas.

Some resistance issues are specific to certain geographic locations.In England, for example, only 1% of P aeruginosa were foundto be resistant to gentamicin, compared with more than 44% ofstrains in Italy, he said.

Escherichia coli resistance to ampicillin is increasingfaster in the United States than in Europe; in contrast E coliresistance to tetracycline is higher in Europe than in the UnitedStates. In some cases, he reiterated, the explanation for suchdiscrepancies may lie in the use of different breakpoints andnonstandard definitions of resistance.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content